Skip to Main content Skip to Navigation
Journal articles

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Cristina Belizna 1, 2 Francesca Pregnolato 3 Sébastien Abad 4, 5 Jaume Alijotas-Reig 6 Howard Amital 7 Zahir Amoura 8 Laura Andreoli 9 Emmanuel Andres 10 Achile Aouba 11 Sule Apras Bilgen 12 Laurent Arnaud 10 Boris Bienvenu 13 Viktoria Bitsadze 14 Patrick Blanco 15 Miri Blank 7 Maria Borghi 16 Antonia Caligaro 17 Elisabeta Candrea 18 Valentina Canti 16 Laurent Chiche 19 Jean Chrétien 1 Jan Willem Cohen Tervaert 20, 21 Laura Damian 22 Teresa Delross 17 Emmanuelle Dernis 23 Katrien Devreese 24 Aleksandra Djokovic 25 Enrique Esteve-Valverde 26 Maria Favaro 17 Céline Fassot 27, 28 Raquel Ferrer-Oliveras 6 Alban Godon 1 Mohamed Hamidou 29 Milena Hasan 30 Daniel Henrion 27, 28 Bernard Imbert 31 Pierre Yves Jeandel 32 Pascale Jeannin 1, 33 Patrick Jego 34 Noemie Jourde-Chiche 35, 36 Jamilya Khizroeva 37 Olivier Lambotte 38, 39 Cédric Landron 40 Jose Omar Latino 41 Estibaliz Lazaro 42 Karina de Leeuw 43 Thomas Le Gallou 34 Levent Kiliç 12 Maarten Limper 44 Laurent Loufrani 27, 28 Romain Lubin 27, 28 Nadine Magy-Bertrand 45 Guillaume Mahé 46, 34 Alexander Makatsariya 37 Thierry Martin 10 Christian Muchardt 47 Gyorgy Nagy Loukman Omarjee 46, 34 Pieter van Paasen 48 Gilles Pernod 49 Florence Perrinet Gilberto Pïres Rosa 50 Marc Antoine Pistorius 29 Amelia Ruffatti 17 Fatma Said 51 Patrick Saulnier 1 Damien Sene 52 Loïc Sentilhes 53 Ova Shovman 7 Jean Sibilia 54 Crina Sinescu 55 Natasa Stanisavljevic 25 Ljudmila Stojanovich 25 Lai Shan Tam 56 Angela Tincani 9 Fréderic Tollis 57 Sebastian Udry 41 Marie Noelle Ungeheuer 58 Mathilde Versini 59 Ricard Cervera 60 Pier Luigi Meroni 16
Abstract : The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01936357
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, November 27, 2018 - 1:33:16 PM
Last modification on : Monday, October 12, 2020 - 10:28:05 AM

Identifiers

Citation

Cristina Belizna, Francesca Pregnolato, Sébastien Abad, Jaume Alijotas-Reig, Howard Amital, et al.. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, Elsevier, 2018, 17 (12), pp.1153 - 1168. ⟨10.1016/j.autrev.2018.05.012⟩. ⟨hal-01936357⟩

Share

Metrics

Record views

855